[Effects of anti-diabetic therapy on cardiovascular disease].
It is debatable whether metabolic control in patients with type 2 diabetes is followed by a commensurate reduction in cardiovascular risk. Large clinical outcome trials have shown that lowering glucose is a poor predictor of cardiovascular outcome; rather a too tight metabolic control exposes patients, particularly those at risk for hypoglycemia, and with renal failure, to severe adverse events. This article reviews the specific effects of the most commonly used glucose-lowering agents on the cardiovascular system, and specifies which drug is best suited for a given clinical condition related to cardiovascular disease.